GINWA(SH:600080) Xin Lang Zheng Quan·2025-10-31 15:27Core Viewpoint - Jinhua Co., Ltd. is a well-known pharmaceutical company in China, established in 1996 and listed in 1997, with a strong focus on drug research, production, and sales, but its revenue and net profit rankings are significantly lower than industry leaders [1][2]. Group 1: Business Performance - For Q3 2025, Jinhua's revenue was 384 million yuan, ranking 59th out of 69 in the industry, significantly lower than the top company, Baiyunshan, with 61.61 billion yuan, and the industry average of 375.5 million yuan [2]. - The net profit for the same period was 34.24 million yuan, ranking 47th out of 69, again far below the leading company, Yunnan Baiyao, which reported 4.789 billion yuan, and the industry average of 447 million yuan [2]. Group 2: Financial Ratios - Jinhua's debt-to-asset ratio was 19.09% in Q3 2025, up from 18.29% the previous year, which is significantly lower than the industry average of 32.81%, indicating a lower debt burden [3]. - The gross profit margin for Q3 2025 was 76.55%, slightly down from 77.98% year-on-year, but still above the industry average of 52.44%, reflecting strong product profitability [3]. Group 3: Executive Compensation - The chairman, Xing Yajiang, received a salary of 1.1203 million yuan in 2024, an increase of 576,000 yuan from 2023 [4]. - The general manager, Han Zhuojun, earned 809,800 yuan in 2024, up by 113,200 yuan from the previous year [4]. Group 4: Shareholder Information - As of September 30, 2025, the number of A-share shareholders decreased by 2.22% to 20,100, while the average number of circulating A-shares held per account increased by 2.27% to 18,600 [5].